The HER2 targeting ADC trastuzumab emtansine, trastuzumab deruxtecan, Trop-2 targeting ADC sacituzumab govitecan, Brentuximab vedotin and enfortumab vedotin has shown great efficacy as neoadjuvant chemotherapy in breast cancer, lymphoma, and invasive urothelial cancer22–27. The gene discussed is TACSTD2; the disease is lymphoma.